Accelerating drug discovery for deadly amoebic diseases

	Drug Discovery
	The latest drug discovery news from News Medical

Rare and neglected infectious diseases remain some of the most challenging conditions to diagnose and treat. One laboratory at Purdue University is dedicated to discovering new therapeutics for infections caused by free-living amoebae – pathogens responsible for severe eye conditions and fatal brain diseases. The lab relies on the WELLJET dispenser stacker and MINI 96 portable electronic pipette from INTEGRA Biosciences to support high throughput drug screening and improve the reproducibility of complex assays.

Read the Article

Streamlining PROTAC Discovery with Direct-to-Biology Workflows

PROTACs are reshaping approaches to difficult therapeutic targets, with the recent FDA approval of vepdegestrant validating TPD as a strategy for previously undruggable proteins. Yet TPD molecule design remains challenging, stretching DMTA cycles to months and consuming significant synthetic and analytical resources. Learn how D2B delivers meaningful efficiency gains in TPD and PROTAC discovery programs.

Access TPD Whitepaper

First-in-class cancer drug gamitrinib evaluated in phase 1 clinical trial

Cancer cells need large amounts of energy to survive and multiply. To produce that energy, they rely on structures inside the cell called mitochondria, often described as the cell's "powerhouse."

	Study potentially opens a new route to more selective cancer drug design Researchers at the Icahn School of Medicine at Mount Sinai have identified a previously hidden druggable site in a cancer-related protein that could open the door toward the development of a new generation of more precise cancer drugs.

	AI breakthrough accelerates molecular simulations for drug discovery A new AI model has become so good at predicting how molecules evolve over time that, in the future, it could speed up the costly and time-consuming process of testing new drugs.

	ELRIG unveils keynote speakers for Drug Discovery 2026 ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, today announced the keynote speaker program for Drug Discovery 2026.

	Advancing Human Muscle Models for Drug Development and Preclinical Testing Transforming drug development, Myomaker Bio's lab-grown muscle platforms offer human-relevant models for effective preclinical testing and risk reduction.

	Introducing Evosep Proteomics to standardize and scale proteomics for research and drug development Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS-based proteomics for research and pharmaceutical drug development.

	Accelerating drug discovery through AI, automation, and next-generation DMTA Discover how AI, automation, and next-generation DMTA workflows are accelerating drug discovery with expert insights from TTP leaders.

	Purdue develops next-generation platform to accelerate cancer drug discovery Researchers at the Purdue Institute for Cancer Research (PICR) have developed a next-generation technology platform designed to dramatically accelerate one of the slowest and most challenging stages of cancer drug discovery: identifying promising compounds that could eventually become new therapies.

How would you rate today's newsletter?

Stay updated with the latest in health and medical news! Follow News‑Medical.net on Google News for real‑time updates. Click here to follow us now.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney | Boston

Copyright © 2000-2026